profit from every $100 of sales.
$0$100
TAO Synergies
$2.54-1.55% today
-67.0% in 1 year
1-year low $2.351-year high $7.70
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What TAO Synergies sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $299,061 in 2025, with -$28.7 million of profit last year.
SalesProfit
TAO Synergies vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| TAO Synergies | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads TAO Synergies's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -16 | -8 | -7 | -9 | |
| -16 | -8 | -7 | -9 | |
| -6 | -6 | -13 | -29 | |
| -20.25 | -29.56 | -10.99 | -8.81 | |
| – | – | – | – | |
| – | – | – | -3,025.2% | |
| – | – | – | -9,609.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 39 | 31 | 18 | 26 |
| Cash | 37 | 29 | 18 | 5 |
| Total debt | – | – | – | – |
| Total liabilities | 3 | 6 | 11 | 4 |
| 35 | 26 | 7 | 22 | |
| 0 | 0 | 1 | 3 | |
| -36.0% | -25.7% | -79.4% | -32.6% | |
| -15.7% | -23.6% | -188.4% | -131.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -11 | -5 | -5 | -6 | |
| 0 | 0 | – | – | |
| -11 | -5 | -5 | -6 | |
| Dividends paid | 0 | 1 | 1 | 0 |
| 0 | 1 | 9 | 1 | |
| 4 | 1 | 0 | 1 |
Valuation
- –
- –
- –
- 0.5×
- 68.3×
- –
- –
- -31.3%
- -140.6%
- 0.0%
Profitability
- 100.0%
- -3,025.2%
- -9,609.2%
- -3,024.0%
- -40.6%
- -79.3%
- -182.5%
- -111.2%
- -40.6%
- 107.7%
Growth
- –
- –
- −30.9%
- –
- –
Financial health
- -0.6×
- 0.00
- 0.0%
- –
- 13.99
- 13.99
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 11%of 958
Bottom 2%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.46 | -12.75 | +96.4% |
| Feb 25, 2026 | -1.04 | – | – |
| Aug 15, 2025 | -11.26 | – | – |
| Dec 31, 2024 | -4.10 | – | – |
| Sep 30, 2024 | -4.35 | – | – |
| Jun 30, 2024 | -1.06 | – | – |
| Mar 31, 2024 | -0.20 | – | – |
News
Definity targets $125M synergies while staying on track for $6.5B 2026 premiums and late-2027 TSA exitsSeeking Alpha · Nov 6, 2026Fox upgraded to Buy at BofA on Roku deal synergies; PT raised to $85Seeking Alpha · Oct 16, 2026Mission Produce forecasts Q4 adjusted EBITDA of $52M-$55M as Calavo synergies target rises to more than $30MSeeking Alpha · Sep 9, 2026Charter closes Cox deal, sees potential for $1B in annual synergiesSeeking Alpha · Aug 21, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/6Passes 1 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
80Pass
Philip Fisher
53No pass
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
49No pass
Terry Smith
45No pass
Questions about TAO Synergies
Is TAO Synergies a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the TAO Synergies AI analysis
What does TAO Synergies do?
Clinical-stage biopharmaceutical company developing a bryostatin‑1 platform for Alzheimer’s and other neurodegenerative/cognitive diseases. Also pivoting to a digital-asset treasury strategy focused on acquiring and staking TAO cryptocurrency. It is in Biotechnology.
Does TAO Synergies pay a dividend?
Yes. In 2025 it paid out $262,087 in dividends.
Is TAO Synergies stock halal?
Yes. TAO Synergies passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has TAO Synergies stock done over the past year?
Down 67.0% over the past twelve months, to $2.54. It traded between $2.35 and $7.70 and is 67.0% below its high.
Who are TAO Synergies's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with TAO Synergies's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.